Single Band vs. Dual Band Pulsed Light Technology for the Treatment of Photodamage - A Split Face Comparison Study

NCT ID: NCT04519736

Last Updated: 2020-08-20

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-05-31
• Study Completion Date: 2014-06-30

Brief Summary

Both the Dye - VL 500 - 600 nm and the Dual band will improve significantly the appearance of Photo Damage with high efficacy including; safety, minimal discomfort and downtime.

Conditions

Photodamage

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Harmony Dye-VL 500-600nm

The left side of the face will be treated with the Single Band Alma Harmony Dye-VL 500-600nm device. Three treatments, administered in intervals of 21 +/- 2 days. Each full face treatment duration will be approximately 20-30 minutes .

Group Type: ACTIVE_COMPARATOR

Single Band vs. Dual Band Pulsed Light Technology for the Treatment of Photodamage

Intervention Type: DEVICE

Palomar MaxG

Right side of the face will be treated with the Dual Band Palomar MaxG device. Three treatments, administered in intervals of 21 +/- 2 days. Each full face treatment duration will be approximately 20-30 minutes .

Group Type: ACTIVE_COMPARATOR

Single Band vs. Dual Band Pulsed Light Technology for the Treatment of Photodamage

Intervention Type: DEVICE

Interventions

Single Band vs. Dual Band Pulsed Light Technology for the Treatment of Photodamage

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

The following are requirements for a potential subject's inclusion into the study:

• Male or female in good general health between 35 to 65 years of age.
• Must be willing to execute informed consent. Patient must also consent to having photos taken at each visit.
• A potential subject must exhibit:

Clinical diagnosis of photo damage affecting the face.

• For FEMALE PATIENTS OF CHILDBEARING POTENTIAL, must have had a regular menstrual cycle prior to study entry (a female is considered of childbearing potential unless she is postmenopausal, without a uterus and/or both ovaries, or has had a bilateral tubal ligation) and is willing to use an acceptable form of birth control during the entire course of the study [i.e., acceptable methods of birth control are oral contraceptives, contraceptive patches/rings/implants Norplanit®, Depo-Provena®, double-barrier methods (e.g. condoms and spermicide), abstinence and vasectomies of partner with a documented second acceptable method of birth control should the subject become sexually active]. All systemic birth control measures must be in consistent use at least 30 days prior to study participation.
• Must be willing to comply with study visits and complete the entire course of the study.

Exclusion Criteria

Subjects meeting any of the following criteria will be excluded from participation:

• A subject that underwent a laser / light treatment on the face within 12 months, or any topical treatment on the face within 6 months.
• A subject with any UNCONTROLLED systemic disease. A potential subject in whom therapy for a systemic disease is not yet stabilized will not be considered for entry into the study.
• A subject with a significant history or current evidence of a medical, psychological or other disorder that, in the investigator's opinion, would preclude enrollment into the study.
• A subject using any topical product containing a retinoid, retinol, or other vitamin A derivative within 3 months prior to or during the study period.
• A subject using any systemic steroid therapy within 6 months prior to or during the study period.
• A subject that has been treated with Botox/Dysport or filler/biostimulatory molecule injections to his/her face within the past 6 months.
• A subject using any topical medicated creams, lotions, powders, etc. on the treatment areas during the study period, other than the study treatment regimen within 14 days.
• A subject that has previously been treated with systemic retinoids within the past year (e.g., Accutane®, Roche Dermatologics).
• A subject with recently excessive facial exposure to sunlight or artificial UV light (e.g.: use of tanning beds/booths and/or sunbathing). During the study, when excessive sun exposure is unavoidable, subjects must wear appropriate protective clothing (e.g. hat, collar) and comply with the study dosing regimen of daily application of the dispersed sunblock.
• A subject with a recent history or active presence of any facial skin condition/disease that might interfere with the diagnosis or evaluation of study parameters (i.e. moderate to severe acne vulgaris, atopic dermatitis, psoriasis, rosacea, seborrheic dermatitis, excessive facial hair or coloration).
• A female subject who is pregnant, nursing an infant or planning a pregnancy during the study [throughout the course of the study, women of child-bearing potential must use reliable forms of contraception (i.e., oral contraceptive, intrauterine device, abstinence, or spermicides and condoms used in combination)].
• Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study.
• Subjects who are pregnant, breast-feeding, or planning a pregnancy. Females of childbearing potential, must be either:

• using the same form (i.e. brand) and dosage regimen of an oral contraceptive pill or of a hormonal implant continuously for 3 months prior to study entry and continue during the entire study, or
• willing to use a different form of birth control during the study other than any form of hormonal methods such as oral contraceptive pills and hormonal implants 30 day prior to study entry and during the entire study period. For the purpose of this study, the following are also considered acceptable methods of birth control: double-barrier methods (e.g.: condoms and spermicide), abstinence and vasectomies of partner with a documented second acceptable method of birth control, should the subject become sexually active.

• Minimum Eligible Age: 35 Years
• Maximum Eligible Age: 60 Years
• Accepts Healthy Volunteers: Yes

Sponsors

Alma Lasers Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Skin Laser & Surgery Specialists of NY/NJ

Hackensack, New Jersey, United States

Countries

United States

Other Identifiers

ALMA-500600-PL12DG

Identifier Type: -

Identifier Source: org_study_id